Some six years after scoring an initial FDA nod in neuromyelitis optica spectrum disorder, Roche’s IL-6 receptor agonist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results